BioNTech and Regeneron Expand Strategic Collaboration to Advance Clinical Development of FixVac and Libtayo® (cemiplimab) Combination in NSCLC
March 08, 2022 08:27 ET
|
BioNTech SE
BioNTech and Regeneron plan to jointly conduct clinical trials evaluating FixVac candidate BNT116 in combination with Libtayo for the treatment of advanced non-small cell lung cancer (NSCLC)The...
Global RNA Stabilization & Delivery Technology Advances Market Report 2021: LNP- and Bioconjugation-based Nonviral RNA Delivery Technologies to Gain Momentum in the Next 3 Years
February 15, 2022 05:43 ET
|
Research and Markets
Dublin, Feb. 15, 2022 (GLOBE NEWSWIRE) -- The "Technological Advances in RNA Stabilization & Delivery" report has been added to ResearchAndMarkets.com's offering. RNA therapeutics is a rapidly...
Xanadu Bio Obtains Licenses and Options to Novel Platform Technologies from Yale University to Develop an Intranasal SARS CoV-2 mRNA Vaccine Booster Aimed at Inducing Local Mucosal Immunity to Prevent SARS CoV-2 Infection and Virus Transmission
February 08, 2022 07:30 ET
|
Xanadu Bio
~ Company licenses PACE, a next generation polymeric nanoparticle delivery platform, and options intranasal PACE/Spike mRNA and Spike recombinant protein vaccine boosters for the treatment of...
Pfizer und BioNTech beginnen klinische Studie zu Omikron-basiertem COVID-19-Impfstoff bei Erwachsenen im Alter von 18-55 Jahren
January 25, 2022 06:45 ET
|
BioNTech SE
Die ersten Teilnehmer erhielten im Rahmen der klinischen Studie den Omikron-basierten Impfstoffkandidaten als Impfserie mit zwei Dosen oder als Auffrischungsimpfung NEW YORK und MAINZ, Deutschland,...
Pfizer and BioNTech Initiate Study to Evaluate Omicron-Based COVID-19 Vaccine in Adults 18 to 55 Years of Age
January 25, 2022 06:45 ET
|
BioNTech SE
First participants enrolled in clinical trial received Omicron-based vaccine candidate as a two-dose primary series and as a booster dose NEW YORK and MAINZ, GERMANY, JANUARY 25, 2022 — Pfizer Inc....
Global microRNA (miRNA) Market Research Report 2021: Increasing Incidence of Infectious Diseases and Chronic Conditions to Help miRNA Market Gallop Ahead
January 19, 2022 06:28 ET
|
Research and Markets
Dublin, Jan. 19, 2022 (GLOBE NEWSWIRE) -- The "microRNA (miRNA) - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering. Global microRNA (miRNA) Market...
Codex DNA Signs Early Access Collaboration and Licensing Agreement with Pfizer to Further Develop Codex DNA’s Novel Enzymatic DNA Synthesis Technology for Pfizer’s use in its Research and Development of mRNA-based Vaccines and Biotherapies
January 10, 2022 06:50 ET
|
Codex DNA, Inc.
Pfizer and Codex DNA agree to strategic, multiyear, early access research collaboration, leveraging Codex DNA’s novel enzymatic DNA synthesis (EDS) technologyPfizer’s successful development and...
The Worldwide RNA Sequencing Industry is Expected to Reach $6+ Billion by 2026
December 20, 2021 06:18 ET
|
Research and Markets
Dublin, Dec. 20, 2021 (GLOBE NEWSWIRE) -- The "RNA Sequencing Market - Forecasts from 2021 to 2026" report has been added to ResearchAndMarkets.com's offering. The global RNA sequencing market is...
Ultragenyx Announces First Patient Dosed in Phase 1/2 Clinical Study of UX053, an mRNA Therapy for the Treatment of Glycogen Storage Disease Type III
December 01, 2021 08:00 ET
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for...
Codex DNA Announces Commercial Availability of Automated mRNA Synthesis Kit with Integrated Capping Technology for BioXp™ System
November 29, 2021 08:03 ET
|
Codex DNA, Inc.
Proven CleanCap® reagent technology from TriLink BioTechnologies delivers significant time and cost savings for mRNA-based vaccine and therapeutic applicationsCodex DNA scientists to share latest data...